Duane Wesemann, MD, PhD

Vaccines are generally designed to train the immune system to combat currently circulating strains of a virus, but a new study offers tantalizing clues that vaccination can, in a sense, anticipate viral evolution.

The research, led by John Dingus, PhD, Duck-Kyun Yoo, PhD, Sachin Kumar, PhD and senior author Duane Wesemann, MD, PhD, from the Mass General Brigham Department of Medicine, suggests that antibodies generated in response to the original COVID-19 vaccines later proved effective against the Omicron variant.

The team found that antibodies made small refinements to their structure, strengthening their grip on regions of the virus that remain relatively stable.

At the same time, the immune system could draw on antibodies with alternative flexible tip configurations, increasing the likelihood that some can still latch onto newly emerging variants, including even highly mutated Omicron lineages.

Overall, the study proposes that antibody strength and flexibility work together to help the immune system cope with future viral changes—insights that may guide the design of vaccines with more durable protection.

Paper Cited:

Dingus, J., Yoo, D. K., Kumar, S., Wang, Y., Kibria, M. G., Saghaei, S., Allahyari, Z., Chen, J. W., Caputo, N. M., Hwang, J., Chen, B., & Wesemann, D. R. (2025). Affinity maturation and light-chain-mediated paratope diversification anticipates viral evolution. Cell reports,  45 (1), 116800. Advance online publication.| Read the paper

Summary reviewed by: Duane Wesemann, MD, PhD, senior author